Naurex Lands $38,000,000 Series B Financing

  • Feed Type
  • Date
    12/17/2012
  • Company Name
    Naurex
  • Mailing Address
    1801 Maple Ave. Evanston, IL 60201
  • Company Description
    Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
  • Website
    http://www.naurex.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Naurex will use the proceeds from the Series B financing to fund a number of key programs from its NMDA receptor modulator platform, including conducting a Phase Ilb trial of GLYX-13, the company’s lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and further developing its second- and third-generation programs for other CNS disorders.
  • M&A Terms
  • Venture Investor
    Baxter Ventures
  • Venture Investor
    Adams Street Partners
  • Venture Investor
    Latterell Venture Partners
  • Venture Investor
    Genesys Capital
  • Venture Investor
    Lundbeckfond Ventures
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    Shire Pharmaceuticals

By posting a comment, you agree to our terms and conditions.